Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with hypertension have a high prevalence of concurrent metabolic abnormalities, including obesity, dyslipidemia, and hyperglycemia. Clustering of these cardiovascular risk factors, defined as metabolic syndrome, causes a more pronounced target organ damage. Aldosterone excess has been found to be associated with glucose disorders and may contribute to cardiovascular damage. OBJECTIVE: The aim of our study was to assess the prevalence and the characteristics of the metabolic syndrome in a group of patients with hypertension due to primary aldosteronism compared with patients with essential hypertension. METHODS: The National Cholesterol Education Program Adult Treatment Panel III definition of the metabolic syndrome was used. Eighty-five patients with primary aldosteronism and 381 patients with essential hypertension were studied. Most patients were not receiving antihypertensive therapy during the investigation. RESULTS: Blood glucose and systolic blood pressure were higher (P < 0.05 and P < 0.01, respectively) and duration of hypertension was longer (P < 0.05) in primary aldosteronism than in essential hypertension. The prevalence of metabolic syndrome was higher in primary aldosteronism than in essential hypertension (41.1% vs. 29.6%; P < 0.05). Distribution of single components of the metabolic syndrome other than hypertension showed a higher prevalence of hyperglycemia in primary aldosteronism than in essential hypertension (27.0% vs. 15.2%; P < 0.05). CONCLUSIONS: Our findings confirm a negative effect of aldosterone excess on glucose metabolism and suggest that the recently reported higher rates of cardiovascular events in primary aldosteronism than in essential hypertension might be due to increased prevalence of the metabolic syndrome in the former condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [6]
In the citing paper
“Higher plasma mineralocorticoid levels may be associated with IR (, ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [166]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.
Modan, M., Halkin, H., Almog, S., Lusky, A., Eshkol, A., Shefi, M., Shitrit, A., & Fuchs, Z. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111776 · Cited by 1,465
Cited by
Items 201–300 of 376
Saha, S., Graessler, J., Schwarz, P. E. H., Goettsch, C., Bornstein, S. R., & Kopprasch, S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1274-2 · Cited by 18
Spironolactone, but not Eplerenone, Impairs Glucose Tolerance in a Rat Model of Metabolic Syndrome
Homma, T., Fujisawa, M., Kiyoshi, A. R. A. I., Ishii, M., Sada, T., & Ikeda, M. (2012) · Journal of Veterinary Medical Science · doi:10.1292/jvms.12-0007 · Cited by 17
Prevalence of Primary Aldosteronism in Hypertensive Subjects with Hyperglycemia
Li, N., Wang, M., Wang, H., Zhang, D., Wang, X., Zu, F.-Y., Chang, G., & Zhou, K. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2012.712175 · Cited by 18
“(25) reported that metabolic syndrome (in particular hyperglycemia) was more prevalent among patients with PA than in patients with essential hypertension.”
BackgroundChan, C., Kim, J. H., Chueh, E., Chang, C., Lin, Y., Lai, T., Huang, K., Lin, Y., & Wu, V. (2019) · Surgery · doi:10.1016/j.surg.2019.05.001 · Cited by 17
Zhang, Z., Luo, Q., Tuersun, T., Wang, G., Wu, T., Zhang, D., Wang, M., Zhou, K., Sun, L., Yue, N., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14318 · Cited by 17
Adrenal steroids and the metabolic syndrome
Thomson, S. P., Stump, C. S., Kurukulasuriya, L. R., & Sowers, J. R. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0093-4 · Cited by 19
“Increased plasma aldosterone may confer increased risk for CVD independent of its effect on hypertension, perhaps due to the presence of more features of the metabolic syndrome [ 55 ].”
BackgroundAldosterone and Metabolic Dysfunction: An Unresolved Issue
Pimenta, E., & Calhoun, D. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.123406 · Cited by 17
Manosroi, W., Atthakomol, P., Watanawittawas, P., & Buranapin, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870047 · Cited by 17
Huang, C. L., Chang, L., Sheu, J.-Y., Huang, Y., Chen, J., Lai, C., & Wu, V. (2025) · Hypertension Research · doi:10.1038/s41440-025-02172-5 · Cited by 16
Saiki, A., Otsuki, M., Tamada, D., Kitamura, T., Shimomura, I., Kurihara, I., Ichijo, T., Takeda, Y., Katabami, T., Tsuiki, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa177 · Cited by 17
Higashide, T., Funabashi, N., Tanaka, T., Inoue, K., Kazama, T., Motoori, K., Nagano, H., Nakatani, Y., Ichikawa, T., Takaoka, H., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.140 · Cited by 16
Hyperaldosteronism: Screening and Diagnostic Tests
Sabbadin, C., & Fallo, F. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0136-5 · Cited by 17
“2 %, respectively) [12], and a more recent study in a large German cohort confirmed a higher prevalence of type 2 diabetes mellitus in PA than in essential hypertensives [13].”
BackgroundSelf-citationZhou, R., Lin, Z., Jiang, C., Gong, J., Chen, L., Guo, Y., & Shen, X. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.47 · Cited by 15
Aldosterone and Hypertension in the Cardiometabolic Syndrome
Stas, S. N., Whaley‐Connell, A. T., & Sowers, J. R. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.08082.x · Cited by 15
Pathophysiology, Diagnosis, and Treatment of Mineralocorticoid Disorders
Magill, S. B. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130042 · Cited by 17
Kaga, M., Utsumi, T., Tanaka, T., Kono, T., Nagano, H., Kawamura, K., Kamiya, N., Imamoto, T., Nihei, N., Naya, Y., et al. (2015) · World Journal of Surgery · doi:10.1007/s00268-015-3197-z · Cited by 15
Krug, A. W., Stelzner, L., Rao, A. D., Lichtman, A. H., Williams, G. H., & Adler, G. K. (2012) · Metabolism · doi:10.1016/j.metabol.2012.08.011 · Cited by 17
“[24] Fallo F, Veglio F, Bertello C, et al.”
Aldosterone and Risk for Insulin Resistance
Whaley‐Connell, A. T., & Sowers, J. R. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.182782 · Cited by 16
Novel methods in adrenal research: a metabolomics approach
Papathomas, T. G., Sun, N., Chortis, V., Taylor, A. E., Arlt, W., Richter, S., Eisenhofer, G., Ruiz-Babot, G., Guasti, L., & Walch, A. K. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01772-w · Cited by 14
Zhang, S.-L., Gao, J., Guo, Y., Feng, Q., Tang, J., Yan, L., Wang, J., Cheng, H., & Liu, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.547356 · Cited by 15
“The final results may thus be easily compared with those found in previous studies (9, 10, 12).”
BackgroundResultMoon, S. J., Jang, H. N., Kim, J. H., & Moon, M. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1012 · Cited by 14
“In several studies comparing PA and EH patients, no significant differences in lipid profiles were observed between the two groups [7-10].”
BackgroundSubtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
Park, S. S., Ahn, C. H., Kim, S. W., Yoon, J. W., & Kim, J. H. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad520 · Cited by 14
Pimenta, E., Gordon, R. D., Ahmed, A. H., Cowley, D., Robson, D., Kogovsek, C., & Stowasser, M. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.102 · Cited by 14
Identification of adrenal genes regulated in a potassium-dependent manner
Dierks, A., Lichtenauer, U. D., Sackmann, S., Spyroglou, A., Shapiro, I., Geyer, M., Manonopoulou, J., Reincke, M., Hantel, C., & Beuschlein, F. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0171 · Cited by 16
Inoue, K., Omura, M., Sugisawa, C., Tsurutani, Y., Saito, J., & Nishikawa, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050948 · Cited by 14
“Detection of PA is critical because hyperaldosteronism increases the prevalence of cardiovascular complications and metabolic syndrome independent of blood pressure [2,3].”
BackgroundPizzolo, F., Zorzi, F., Chiecchi, L., Consoli, L., Aprili, I., Guarini, P., Castagna, A., Salvagno, G. L., Pavan, C., & Olivieri, O. (2013) · Endocrine · doi:10.1007/s12020-013-0028-6 · Cited by 13
Diagnosis and Management of Primary Aldosteronism
(2011) · The Nurse Practitioner · doi:10.1097/01.npr.0000396310.36814.a6 · Cited by 13
Treatment of primary aldosteronism: Where are we now?
Karagiannis, A. I. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9159-3 · Cited by 13
“The metabolic syndrome has also been reported to be more prevalent among patients with PA than in patients with essential hypertension [21, 22].”
BackgroundDevelopments in Primary Aldosteronism Subtyping Using Steroid Profiling
Wannachalee, T., & Turcu, A. F. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1141-3526 · Cited by 14
Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism
Jahan, S., Yang, J., Hu, J., Li, Q., & Fuller, P. J. (2024) · Endocrine Connections · doi:10.1530/ec-23-0445 · Cited by 12
Aldosterone, mitochondria and regulation of cardiovascular metabolic disease
Tsai, C., Chen, Z., Lee, B., Liao, C., Chang, Y., Tsai, Y.-R., Chou, C., Wu, V., Hung, C., & Lin, Y. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0350 · Cited by 12
Castro, M. A., Rojano, N. B., Argüeso, M. F., Corrales, E. P., Mendiguchía, L. J., & Cano, A. M. G. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.07.025 · Cited by 12
Aldosterone Excess and Resistant Hypertension: Investigation and Treatment
Stowasser, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0439-7 · Cited by 12
Martínez‐Aguayo, A., Carvajal, C. A., Campino, C., Marlene Aglony, I., Bolte, L., García, H., & Fardella, C. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.052 · Cited by 12
Liu, G.-Z., Zhang, S., Li, Y., Liu, Y., Zhang, Y., Xin-bo, Z., Yuan, Y., Zhang, J.-W., Khannanova, Z., & Li, Y. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01641-2 · Cited by 12
Grillo, A., Bernardi, S., Rebellato, A., Fabris, B., Bardelli, M., Burrello, J., Rabbia, F., Veglio, F., Fallo, F., & Carretta, R. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12551 · Cited by 12
“The reasons for patient referral were onset of high BP at a young age, hypertension resistant to conventional antihypertensive treatment, hypertension with unexplained spontaneous or diureticinduced hypokalemia, elevated plasma aldosterone, low plasma renin activity (PRA), and an adrenal incidentaloma.(11) Thirty heal…”
MethodSelf-citationWang, J., Hu, H., Song, J., Yan, F., Qin, J., Guo, X., Cui, C., He, Q., Hou, X., Liu, F., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.149 · Cited by 11
Primary Aldosteronism and Ischemic Heart Disease
Patil, S. P., Rojulpote, C., & Amanullah, A. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.882330 · Cited by 11
“Clustering of hypertension, abdominal obesity, dyslipidemia and impaired glucose metabolism, is more commonly encountered in PA patients than individuals with essential hypertension (21, 22).”
BackgroundTreatment of Primary Aldosteronism With mTORC1 Inhibitors
Trinh, B., Hepprich, M., Betz, M. J., Burkard, T., Cavelti‐Weder, C., Seelig, E., Meienberg, F., Kratschmar, D. V., Beuschlein, F., Reincke, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00563 · Cited by 11
“Compared with age-, sex- and blood pressure-matched patients with essential hypertension, patients with PA have an increased ri sk of cardio- and cerebrovascular morbidity and mortality (3,4), structural and funct ional renal abnormalities (5,6) and metabolic syndrome (7).”
BackgroundPrimary Aldosteronism: a Continuum from Normotension to Hypertension
Wannachalee, T., & Turcu, A. F. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01538-8 · Cited by 11
Castro, M. A., Corrales, E. P., Rojas, P. M., & Ramírez, P. A. P. (2023) · Endocrine · doi:10.1007/s12020-023-03573-7 · Cited by 11
Aldosterone Action on Brain and Behavior
Murck, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00052-3 · Cited by 10
Jiang, S.-B., Guo, X., Wang, H., Gong, R., Hui, X., Wang, Z., Zhang, H., & Jin, X. (2014) · International Urology and Nephrology · doi:10.1007/s11255-013-0614-9 · Cited by 10
“Meanwhile, lowering plasma aldosterone concentration can reduce related complications such as myocardial infarction [18], cerebral infarction, left ventricular hypertrophy [14], atherosclerosis [15], metabolic syndrome [18], renal vascular alterations [19], etc.”
BackgroundThe mineralocorticoid receptor: a new player controlling energy homeostasis
Kuhn, E., & Lombès, M. (2013) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2013-0033 · Cited by 10
Bokuda, K., Yatabe, M., Mizuguchi, Y., Niiyama, M., Seki, Y., Watanabe, D., Yatabe, J., Ando, T., Morimoto, S., & Ichihara, A. (2017) · Hypertension Research · doi:10.1038/hr.2017.78 · Cited by 10
Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome
Pitt, B. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04117 · Cited by 9
Mansouri, K., Greupner, T., & Hahn, A. (2023) · Blood Pressure · doi:10.1080/08037051.2023.2291411 · Cited by 9
“Additionally, it has been demonstrated that the prevalence of the metabolic syndrome increases with pathologically elevated serum aldosterone levels [36, 43].”
Primary aldosteronism: A Japanese perspective
Satoh, F., Morimoto, R., Iwakura, Y., Ono, Y., Kudo, M., Takase, K., & Ito, S. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9161-9 · Cited by 9
“Therefore, the choice of a confirmatory test is determined by cost, patient compliance and local expertise, and still remains a matter of debate [19, 20].”
Circadian hemodynamic characteristics in hypertensive patients with primary aldosteronism
Kusunoki, H., Iwashima, Y., Kawano, Y., Hayashi, S.-I., Kishida, M., Horio, T., Shinmura, K., & Yoshihara, F. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001800 · Cited by 9
The risk factors for hepatic steatosis in patients with primary aldosteronism
Shibayama, Y., Wada, N., Baba, S., Obara, S., Sakai, H., Usubuchi, H., Terae, S., Nakamura, A., & Atsumi, T. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0600 · Cited by 9
“However, PA is compli‐ cated not only by hypertension, but also by the presence of insulin resistance and dyslipidemia, meaning that car‐ diovascular disease is more prevalent in individuals with PA than in those without [3, 4].”
BackgroundVoulgaris, N., Tyfoxylou, E., Vlachou, S., Kyriazi, E., Gravvanis, C., Kapsali, C., Markou, Α., Papanastasiou, L., Gryparis, A., Kassi, E. N., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1507-5226 · Cited by 9
Chiang, J., Chen, C., Tseng, F., Chi, Y., Huang, K., & Yang, W. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0175-6 · Cited by 9
Kuo, C., Balakrishnan, P., Hsein, Y.-C., Wu, V., Chueh, S., Chen, Y.-M., Wu, K., Wang, M., TAIPAI group, Wu, V., et al. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313498632 · Cited by 9
“, 200973 408 60 (10) 12 (9) Germany Somloova et al.”
Genetic aspects of primary hyperaldosteronism
Korzyńska, W., Jodkowska, A., Gosławska, K., Bogunia‐Kubik, K., & Mazur, G. J. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/69390 · Cited by 8
Johnson, T. A., Fettweis, G., Wagh, K., Almeida‐Prieto, B., Krishnamurthy, M., Upadhyaya, A., Hager, G. L., & de la Rosa, D. Á. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.26.525745 · Cited by 8
“Conversely, an excess of mineralocorticoids can mimic glucocorticoid effects, such as glucose homeostasis dysregulation and development of metabolic syndrome (2).”
Sun, K., Zhou, C., Gong, M., Zhang, Y., Jiang, Y., & Song, W. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14873 · Cited by 8
Aldosterone is not Involved in the Ventricular Remodeling Process Induced by Tobacco Smoke Exposure
Santos, D., Nogueira, B. F., Rafacho, B. P. M., Azevedo, P. S., Polegato, B. F., Chiuso‐Minicucci, F., Bonomo, C., Roscani, M. G., Zorzella-Pezavento, S. F. G., Tanni, S. É., et al. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000343309 · Cited by 7
Pan, L.-H., Chen, Y.-Y., Pan, C., Hsu, C., Tseng, C., Yen, I., Chan, C., & Lin, L. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.08.010 · Cited by 7
Song, J., Cai, J., Ma, W., Lou, Y., Bian, J., Zhao, B., She, X., & Liu, X. ‐. (2024) · Biomedical Chromatography · doi:10.1002/bmc.5855 · Cited by 7
Vedere, T., & Khalifa, M. (2025) · Urologic Clinics of North America · doi:10.1016/j.ucl.2025.01.003 · Cited by 7
Kao, C., Wu, V., Kuo, C.-C., Lin, Y., Hu, Y.-H., Tsai, Y., Wu, C., Wu, K., & TAIPAI study group (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312452767 · Cited by 7
Huang, X., Yu, S., Xiao, H., Pei, L., Chen, Y., Chen, W., Li, Y., Xiao, H., & Cao, X. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6685469 · Cited by 7
“patients with EH [8, 9, 18], while some other studies hold opposite opinions [12, 13].”
ResultFardella, C., Mosso, L. M., & Carvajal, C. A. (2008) · Revista médica de Chile · doi:10.4067/s0034-98872008000700014 · Cited by 7
Castro, M. A., Paja, M., Peris, B. P., Boillos, M. G., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Ruiz-Sánchez, J. G., Delgado, A. V., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02090-8 · Cited by 7
Resistant hypertension—complex mix of secondary causes and comorbidities
Dudenbostel, T. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.46 · Cited by 7
Clinical Characteristics and Long-Term Outcome of Primary Aldosteronism in a Norwegian Population
Grytaas, M. A., Strømsøy, S., Rørvik, J. T., Arnes, J. B., Heie, A., Arnesen, T., Jørstad, M. D., Nedrebø, B. G., Jøssang, D. E., Jensen, D., et al. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-118909 · Cited by 9
Pillai, K. V., Fares, A., Dargham, S. R., Suwaidi, J. M. S. A., Jayyousi, A., & Khalil, C. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1147225 · Cited by 6
“Hypertension in PA is associated with left ventricular hypertrophy (LVH), stroke, renal dysfunction (9), and impaired glucose metabolism (10).”
BackgroundThe mineralocorticoid system, cardiometabolic health and its interplay with adipose tissue
Thuzar, M., Halim, M. A., & Stowasser, M. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0119 · Cited by 6
Bansal, S., Puzantian, H. V., & Townsend, R. R. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09081-2 · Cited by 8
“28 Although in this study, out of all the components of metabolic syndrome, in addition to hypertension, only hyperglycemia was significantly more prevalent in PA than in essential hypertension (27.0% vs. 15.2%; p < 0.05).”
InfluentialBu, X., Sun, F., Zhang, H., Liu, X., Zhao, Z., He, H., Li, Y., Yan, Z., & Zhu, Z. (2022) · Journal of Diabetes Research · doi:10.1155/2022/8932133 · Cited by 6
Prevalence of primary aldosteronism among bulgarian hypertensive patients
Matrozova, J., Zacharieva, S., Кirilov, G., & Boyanov, M. (2010) · Open Medicine · doi:10.2478/s11536-010-0005-x · Cited by 6
“Both in vitro and clinical studies have described a possible association between PA and carbohydrate metabolism disorders, pointing out aldosterone as a potential contributing factor in the development of the metabolic syndrome and insulin resistance [21-23].”
Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: a meta-analysis
Jia, M., Zhang, H., Song, X., Pang, X., Ye, W.-L., Miao, W., & Gu, W. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0455 · Cited by 7
Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection
Chan, C., Chang, Y., Tsai, Y., Chen, Z., Wu, C.-Y., Huang, W., Yen, I., Wu, K.-H., Wu, V., Lin, Y., et al. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.03.032 · Cited by 6
Effects of Aldosterone on Chemerin Expression And Secretion in 3T3-L1 Adipocytes
Ma, J., Sun, F., Wang, J., Jiang, H., Lu, J., Wang, X., Zhang, J., Shi, C., You, W., Li, X., et al. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-118749 · Cited by 6
Primary Mineralocorticoid Excess Disorders and Hypertension
Carey, R. M., & Padia, S. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00108-6 · Cited by 6
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism
Tizianel, I., Madinelli, A., Crimì, F., Barbot, M., Censi, S., Sabbadin, C., & Ceccato, F. (2025) · Clinical Endocrinology · doi:10.1111/cen.15231 · Cited by 5
“Other concurrent environmental factors, such as hypokalemia, may impair insulin action [5].”
Barrea, L., Caprio, M., Perrini, S., Camajani, E., Crafa, A., Gangitano, E., Gorini, S., Sciacca, L., Verde, L., Albertelli, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02589-2 · Cited by 5
“This observation clearly suggests that excessive activation of mineralocorticoid receptors has a relevant role in metabolic dysfunctions observed in individuals with primary aldosteronism [ 80 ].”
Buonacera, A., Stancanelli, B., & Malatino, L. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0200-9 · Cited by 5
Lee, M.-J., Sun, C., Lu, C., Chang, Y.-S., Pan, H., Lin, Y., Wu, V., & Chueh, S. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622321990274 · Cited by 5
Feline primary hyperaldosteronism: an emerging endocrine disease
Bento, D. D., Zahn, F. S., Duarte, L. C., & Machado, L. H. D. A. (2016) · Ciência Rural · doi:10.1590/0103-8478cr20141327 · Cited by 5
Screening for primary aldosteronism in the diabetic population: a cohort study
Tan, S. J., Libianto, R., Yang, J., & Wong, J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15690 · Cited by 5
Adrenal–adipose tissue crosstalk in health and disease
Jiang, M., Stifel, U., Blüher, M., Lefèbvre, H., Bornstein, S. R., & Bechmann, N. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf252 · Cited by 4
Role of Aldosterone in Insulin Resistance: Fact of Fantasy
Sechi, L. A., & Colussi, G. (2015) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000161 · Cited by 4
“An increased prevalence of the metabolic syndrome was reported in a large group of patients with PA in comparison to essential hypertensive controls [15].”
BackgroundMedical Treatment of Primary Aldosteronism
Takeda, Y., Demura, M., & Yoneda, T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0509-6_14 · Cited by 4
Association of Papillary Thyroid Carcinoma with Primary Aldosteronism
NAKAMURA, S., Ishimori, M., & Yamakita, N. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0891-18 · Cited by 5
Ye, F., Tang, Z., Wu, J., Yang, Y., Tian, X., Huang, J., Zhang, S., & Ning, G. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12070 · Cited by 4
“Our results showing similar BP in different subtypes of PA coincide with previous reports but partly differ from other studies.(5,6,9) Most of the patients with PA received long-acting CCBs, which might diminish the difference in level of BP, because it may have a stronger influence in patients with higher BP than in…”
ResultIssues in the Diagnosis and Treatment of Primary Aldosteronism
Burrello, J., Monticone, S., Buffolo, F., Tetti, M., Giraudo, G., Schiavone, D., Veglio, F., & Mulatero, P. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0084-5 · Cited by 4
“Studies comparing patients with PA to those with essential hypertension have consistently shown that the former have a higher prevalence of left ventricular hypertrophy, coronary artery disease, heart failure, atrial fibrillation [8], metabolic syndrome [9], prolonged QT interval [10], microalbuminuria [11] and endoth…”
BackgroundSelf-citationMories, M. T. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73190-4 · Cited by 4
Babińska, A., Kmieć, P., & Sworczak, K. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.93486 · Cited by 4
Castro, M. A., Rojano, N. B., Argüeso, M. F., Corrales, E. P., Mendiguchía, L. J., & Cano, A. M. G. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.07.049 · Cited by 4
Zhang, C., Jiang, Y., Su, T., Jiang, L., Zhou, W., Zhong, X., Wu, L., & Wang, W. (2022) · Endocrine · doi:10.1007/s12020-022-03095-8 · Cited by 4
Metabolic Dysfunction in Primary Aldosteronism
Sechi, L. A., Colussi, G., & Catena, C. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.132951 · Cited by 4
Have Main Types of Primary Aldosteronism Different Phenotype?
Šomlóová, Z., Indra, T., Rosa, J., Petrák, O., Štrauch, B., Zelinka, T., Holaj, R., & Widimsky, J., Jr. (2012) · Physiological Research · doi:10.33549/physiolres.932335 · Cited by 4
Call for screening for primary aldosteronism: an underdiagnosed and treatable disease
TAIPAI Study Group, Er, L., & Wu, V. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.71 · Cited by 4
Clinical manifestations of primary aldosteronism and cardiometabolic risk
Corrales, E. P., Ruiz-Cánovas, J. M., & Perez-Peña, M. M. (2025) · Vitamins and hormones · doi:10.1016/bs.vh.2025.08.002 · Cited by 4
Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte
Armani, A., Gorini, S., Feraco, A., Mammi, C., Bellucci, E., & Caprio, M. (2026) · Endocrinology · doi:10.1210/endocr/bqag004 · Cited by 3
Krieg, A. H., Krieg, S., Heuser, A., Laverenz, U., Istrate, V.-A., Schott, M., & Kostev, K. (2024) · Biomedicines · doi:10.3390/biomedicines12112479 · Cited by 3
“Additionally, metabolic disorders like type 2 diabetes and metabolic syndrome [19,21,22], psychiatric changes [23], and obstructive sleep apnea syndrome (OSAS) [24] are increasingly observed in patients with PA.”
Insulin signaling in adipose tissue of patients with primary aldosteronism
Urbanet, R., Pilon, C., Giorgino, F., Vettor, R., & Fallo, F. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347035 · Cited by 3
Self-citation「わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント」(全文)
(2016) · Folia Endocrinologica Japonica · doi:10.1507/endocrine.92.suppl.september_1 · Cited by 3
SCHTEINGART, D. E. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79570-6 · Cited by 3
Metadata
- Authors
- Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P.
- Affiliations
- University of Padua (IT)
- University of Turin (IT)
- Corresponding author
- Fallo, Francesco
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-02
- Volume
- 91
- Issue
- 2
- Pages
- 454-459
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099583783
- Semantic Scholar
- 5b2795dc0ee3d66f4f0cf0367b9210dd5492663a
- Cited by
- 372
- References
- 61
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 16 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 23 · 2016: 18 · 2015: 17 · 2014: 17 · 2013: 22 · 2012: 23
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, metabolic syndrome, essential hypertension, hyperglycemia, aldosterone excess, glucose metabolism, cardiovascular risk, dyslipidemia, obesity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Female, Humans, Hyperaldosteronism, Hypertension, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Triglycerides, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.